-

BIOCORP: Its Range of Connected Devices Featured at Several International Conferences and Exhibitions

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today its participation in the following trade shows:

  • Connect in Pharma (The Future of Packaging, Drug Delivery & Contract Manufacturing), September 14-15, 2022, Geneva, Switzerland
  • 2022 PDA (Universe of Pre-Filled Syringes and Injection Devices Conference), October 18-19, 2022, in Palm Springs, California (USA)
  • PODD (Partnerships Opportunities in Drug Delivery), October 24-25, 2022, Boston, Massachusetts (USA)
  • CPHI Worldwide, November 1-3, 2022, Frankfurt, Germany

Within the framework of these international exhibitions, BIOCORP will present its range of connected smart devices: the latest miniaturized versions of Mallya for injection pens, Injay for pre-filled syringes, as well as new products such as Sween, a reusable needle insertor to assist patients in the self-injection of drugs.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.

Contacts

CONTACTS BIOCORP
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

BIOCORP

BOURSE:ALCOR

Release Versions

Contacts

CONTACTS BIOCORP
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Social Media Profiles
More News From BIOCORP

BIOCORP Obtains 510(k) FDA Clearance for SoloSmart®, Sanofi’s Smart Cap for Disposable Insulin Pens

ISSOIRE, France--(BUSINESS WIRE)--Press Release BIOCORP (Paris:ALCOR), a Novo Nordisk company based in France and specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market SoloSmart®, Sanofi’s smart medical device that connects SoloStar® insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for SoloSmart and ou...

BIOCORP Reports Half-year Results as of June 30, 2023

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its half-year financial results as of June 30, 20231. Éric Dessertenne, CEO of BIOCORP, commented: “The first half of 2023 has been very dynamic for Biocorp with the main event being the conclusion of discussions with NOVO NORDISK, our commercial partner of the Mallya...

Completion of Novo Nordisk's Acquisition of a Controlling Stake in BIOCORP

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: Following the announcement of the planned acquisition of BIOCORP Production SA (FR0012788065 - ALCOR) (“BIOCORP”) by NOVO NORDISK (DK0060534915 - Novo-B), a leading global healthcare company headquartered in Denmark and developing treatments against diabetes and other chronic diseases (“NOVO NORDISK”), released on June 5, 2023, BIOCORP announces that, following receipt of customary regulatory approvals, NOVO NORDISK has today completed the off-...
Back to Newsroom